{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:12:19Z","timestamp":1791472339948,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,29]]},"DOI":"10.7759\/cureus.44341","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T19:57:18Z","timestamp":1693339038000},"source":"Crossref","is-referenced-by-count":27,"title":["Comparing the Safety and Efficacy of Proton Pump Inhibitors and Histamine-2 Receptor Antagonists in the Management of Patients With Peptic Ulcer Disease: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Maha","family":"Begg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mawada","family":"Tarhuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"N. Fotso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie A","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavendra R","family":"Sanivarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abishek","family":"Latha Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Sadagopan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Peptic ulcer disease and Helicobacter pylori infection","volume":"115","author":"Narayanan M","year":"2018","unstructured":"Narayanan M, Reddy KM, Marsicano E. Peptic ulcer disease and Helicobacter pylori infection. Mo Med. 2018, 115:219-24.","journal-title":"Mo Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2105\/ajph.86.2.200","article-title":"The prevalence of self-reported peptic ulcer in the United States","volume":"86","author":"Sonnenberg A","year":"1996","unstructured":"Sonnenberg A, Everhart JE. The prevalence of self-reported peptic ulcer in the United States. Am J Public Health. 1996, 86:200-5. 10.2105\/ajph.86.2.200","journal-title":"Am J Public Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30037-2","article-title":"Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials","volume":"3","author":"Scally B","year":"2018","unstructured":"Scally B, Emberson JR, Spata E, et al.. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018, 3:231-41. 10.1016\/S2468-1253(18)30037-2","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5009\/gnl15502","article-title":"25 years of proton pump inhibitors: a comprehensive review","volume":"11","author":"Strand DS","year":"2017","unstructured":"Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017, 11:27-37. 10.5009\/gnl15502","journal-title":"Gut Liver"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-013-0012-x","article-title":"Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics","volume":"15","author":"Ward RM","year":"2013","unstructured":"Ward RM, Kearns GL. Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs. 2013, 15:119-31. 10.1007\/s40272-013-0012-x","journal-title":"Paediatr Drugs"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2011.05.001","article-title":"Peptic ulcer disease","volume":"38","author":"Najm WI","year":"2011","unstructured":"Najm WI. Peptic ulcer disease. Prim Care. 2011, 38:383-94, vii. 10.1016\/j.pop.2011.05.001","journal-title":"Prim Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.23736\/S0391-1977.17.02745-6","article-title":"Diagnosis and management of Zollinger-Ellison syndrome in 2018","volume":"43","author":"De Angelis C","year":"2018","unstructured":"De Angelis C, Cortegoso Valdivia P, Venezia L, Bruno M, Pellicano R. Diagnosis and management of Zollinger-Ellison syndrome in 2018. Minerva Endocrinol. 2018, 43:212-20. 10.23736\/S0391-1977.17.02745-6","journal-title":"Minerva Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000331517","article-title":"Complications of peptic ulcer disease","volume":"29","author":"Milosavljevic T","year":"2011","unstructured":"Milosavljevic T, Kosti\u0107-Milosavljevi\u0107 M, Jovanovi\u0107 I, Krsti\u0107 M. Complications of peptic ulcer disease. Dig Dis. 2011, 29:491-3. 10.1159\/000331517","journal-title":"Dig Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002296","article-title":"Prevention of NSAID\u2010induced gastroduodenal ulcers","volume":"2002","author":"Rostom A","year":"2002","unstructured":"Rostom A, Dube C, Wells GA, et al.. Prevention of NSAID\u2010induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002, 2002:CD002296. 10.1002\/14651858.CD002296","journal-title":"Cochrane Database Syst Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/gut.32.4.435","article-title":"Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial","volume":"32","author":"Bardhan KD","year":"1991","unstructured":"Bardhan KD, Naesdal J, Bianchi Porro G, et al.. Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial. Gut. 1991, 32:435-8. 10.1136\/gut.32.4.435","journal-title":"Gut"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/gut.30.10.1323","article-title":"Randomised, double blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer","volume":"30","author":"Bate CM","year":"1989","unstructured":"Bate CM, Wilkinson SP, Bradby GV, et al.. Randomised, double blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer. Gut. 1989, 30:1323-8. 10.1136\/gut.30.10.1323","journal-title":"Gut"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/gut.30.9.1173","article-title":"Double blind multicentre comparison of omeprazole 20 mg once daily versus ranitidine 150 mg twice daily in the treatment of cimetidine or ranitidine resistant duodenal ulcers","volume":"30","author":"Delchier JC","year":"1989","unstructured":"Delchier JC, Isal JP, Eriksson S, Soule JC. Double blind multicentre comparison of omeprazole 20 mg once daily versus ranitidine 150 mg twice daily in the treatment of cimetidine or ranitidine resistant duodenal ulcers. Gut. 1989, 30:1173-8. 10.1136\/gut.30.9.1173","journal-title":"Gut"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00179.x","article-title":"Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice","volume":"11","author":"Jones RH","year":"1997","unstructured":"Jones RH, Baxter G. Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther. 1997, 11:541-6. 10.1046\/j.1365-2036.1997.00179.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/gut.29.2.249","article-title":"Effect of omeprazole and cimetidine on prepyloric gastric ulcer: double blind comparative trial","volume":"29","author":"Lauritsen K","year":"1988","unstructured":"Lauritsen K, Rune SJ, Wulff HR, et al.. Effect of omeprazole and cimetidine on prepyloric gastric ulcer: double blind comparative trial. Gut. 1988, 29:249-53. 10.1136\/gut.29.2.249","journal-title":"Gut"},{"key":"ref16","article-title":"Optimal use of proton pump inhibitors for treating acid peptic diseases in primary care","volume":"76","author":"Tack J","year":"2013","unstructured":"Tack J, Louis E, Persy V, Urbain D. Optimal use of proton pump inhibitors for treating acid peptic diseases in primary care. Acta Gastroenterol Belg. 2013, 76:393-402.","journal-title":"Acta Gastroenterol Belg"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.09.036","article-title":"Proton pump inhibitor use represents an independent risk factor for myocardial infarction","volume":"177","author":"Shih CJ","year":"2014","unstructured":"Shih CJ, Chen YT, Ou SM, Li SY, Chen TJ, Wang SJ. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol. 2014, 177:292-7. 10.1016\/j.ijcard.2014.09.036","journal-title":"Int J Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-012-2112-9","article-title":"The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study","volume":"24","author":"Fraser LA","year":"2013","unstructured":"Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013, 24:1161-8. 10.1007\/s00198-012-2112-9","journal-title":"Osteoporos Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.316","article-title":"The association of proton pump inhibitors and hypomagnesemia in the community setting","volume":"54","author":"Markovits N","year":"2014","unstructured":"Markovits N, Loebstein R, Halkin H, Bialik M, Landes-Westerman J, Lomnicky J, Kurnik D. The association of proton pump inhibitors and hypomagnesemia in the community setting. J Clin Pharmacol. 2014, 54:889-95. 10.1002\/jcph.316","journal-title":"J Clin Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.179","article-title":"Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis","volume":"107","author":"Janarthanan S","year":"2012","unstructured":"Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012, 107:1001-10. 10.1038\/ajg.2012.179","journal-title":"Am J Gastroenterol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.4791","article-title":"Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis","volume":"73","author":"Gomm W","year":"2016","unstructured":"Gomm W, von Holt K, Thom\u00e9 F, et al.. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016, 73:410-6. 10.1001\/jamaneurol.2015.4791","journal-title":"JAMA Neurol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-017-4725-5","article-title":"Associations of proton-pump inhibitors and H2 receptor antagonists with chronic kidney disease: a meta-analysis","volume":"62","author":"Wijarnpreecha K","year":"2017","unstructured":"Wijarnpreecha K, Thongprayoon C, Chesdachai S, Panjawatanana P, Ungprasert P, Cheungpasitporn W. Associations of proton-pump inhibitors and H2 receptor antagonists with chronic kidney disease: a meta-analysis. Dig Dis Sci. 2017, 62:2821-7. 10.1007\/s10620-017-4725-5","journal-title":"Dig Dis Sci"},{"key":"ref23","article-title":"Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis","volume":"7","author":"Eriksson S","year":"1995","unstructured":"Eriksson S, L\u00e5ngstr\u00f6m G, Rikner L, Carlsson R, Naesdal J. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. Eur J Gastroenterol Hepatol. 1995, 7:467-75.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref24","article-title":"Rates of duodenal ulcer (DU) healing by drug classes: a meta-analysis","volume":"104","author":"Morgan DG","year":"1993","unstructured":"Morgan DG, Burget DW, Howden CW, et al.. Rates of duodenal ulcer (DU) healing by drug classes: a meta-analysis. Gastroenterology. 1993, 104:150.","journal-title":"Gastroenterology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-010-1209-2","article-title":"Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement?","volume":"55","author":"Chey WD","year":"2010","unstructured":"Chey WD, Mody RR, Izat E. Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement?. Dig Dis Sci. 2010, 55:3415-22. 10.1007\/s10620-010-1209-2","journal-title":"Dig Dis Sci"},{"key":"ref26","unstructured":"FDA drug safety communication. low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). (2011). Accessed: 2023: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-low-magnesium-levels-can-be-asso...."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.092129","article-title":"Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis","volume":"183","author":"Eom CS","year":"2011","unstructured":"Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011, 183:310-9. 10.1503\/cmaj.092129","journal-title":"CMAJ"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.12.011","article-title":"Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis","volume":"11","author":"Lo WK","year":"2013","unstructured":"Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013, 11:483-90. 10.1016\/j.cgh.2012.12.011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref29","article-title":"pH, healing rate and symptom relief in acid-related diseases","volume":"69","author":"Huang JQ","year":"1996","unstructured":"Huang JQ, Hunt RH. pH, healing rate and symptom relief in acid-related diseases. Yale J Biol Med. 1996, 69:159-74.","journal-title":"Yale J Biol Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1269","article-title":"Balancing the risks and benefits of proton pump inhibitors","volume":"9","author":"Gill JM","year":"2011","unstructured":"Gill JM, Player MS, Metz DC. Balancing the risks and benefits of proton pump inhibitors. Ann Fam Med. 2011, 9:200-2. 10.1370\/afm.1269","journal-title":"Ann Fam Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)80009-x","article-title":"Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse. Double-blind comparative trial","volume":"100","author":"Lauritsen K","year":"1991","unstructured":"Lauritsen K, Andersen BN, Laursen LS, et al.. Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse. Double-blind comparative trial. Gastroenterology. 1991, 100:663-9. 10.1016\/0016-5085(91)80009-x","journal-title":"Gastroenterology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1993.tb00595.x","article-title":"Efficacy of continuous therapy for peptic ulcer in controlled clinical trials","volume":"7 Suppl 2","author":"Dammann HG","year":"1993","unstructured":"Dammann HG, Walter TA. Efficacy of continuous therapy for peptic ulcer in controlled clinical trials. Aliment Pharmacol Ther. 1993, 7 Suppl 2:17-25. 10.1111\/j.1365-2036.1993.tb00595.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868070-00004","article-title":"Guide to the use of proton pump inhibitors in adult patients","volume":"68","author":"Boparai V","year":"2008","unstructured":"Boparai V, Rajagopalan J, Triadafilopoulos G. Guide to the use of proton pump inhibitors in adult patients. Drugs. 2008, 68:925-47. 10.2165\/00003495-200868070-00004","journal-title":"Drugs"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04874.x","article-title":"Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection","volume":"34","author":"Bavishi C","year":"2011","unstructured":"Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011, 34:1269-81. 10.1111\/j.1365-2036.2011.04874.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/821385","article-title":"Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials","volume":"22","author":"Sultan N","year":"2008","unstructured":"Sultan N, Nazareno J, Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol. 2008, 22:761-6. 10.1155\/2008\/821385","journal-title":"Can J Gastroenterol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang YX","year":"2006","unstructured":"Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006, 296:2947-53. 10.1001\/jama.296.24.2947","journal-title":"JAMA"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.8.951","article-title":"Proton pump inhibitor use and risk of hip fractures in patients without major risk factors","volume":"28","author":"Kaye JA","year":"2008","unstructured":"Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008, 28:951-9. 10.1592\/phco.28.8.951","journal-title":"Pharmacotherapy"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-304738","article-title":"Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis","volume":"63","author":"Filion KB","year":"2014","unstructured":"Filion KB, Chateau D, Targownik LE, et al.. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut. 2014, 63:552-8. 10.1136\/gutjnl-2013-304738","journal-title":"Gut"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.08.023","article-title":"Safety of proton pump inhibitor exposure","volume":"139","author":"Yang YX","year":"2010","unstructured":"Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010, 139:1115-27. 10.1053\/j.gastro.2010.08.023","journal-title":"Gastroenterology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/163652-comparing-the-safety-and-efficacy-of-proton-pump-inhibitors-and-histamine-2-receptor-antagonists-in-the-management-of-patients-with-peptic-ulcer-disease-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:56:16Z","timestamp":1707508576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/163652-comparing-the-safety-and-efficacy-of-proton-pump-inhibitors-and-histamine-2-receptor-antagonists-in-the-management-of-patients-with-peptic-ulcer-disease-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.44341","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,29]]}}}